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http://dxObjective: To investigate the resuscitation potential and contractile function in adult human donation after
cardiac death (DCD) hearts by ex vivo perfusion.
Methods:With institutional review board approval and under the DCD protocol at the University of Wisconsin
(UW) Organ Procurement Organization, 5 brain dead (BD) and 5 DCD donor hearts were evaluated. All BD
hearts were declined for clinical transplantation because of coronary artery disease, advanced age, or social his-
tory. All hearts were preserved by flushing and cold storage with UW solution. By using our ex vivo perfusion
system, the left ventricular end systolic pressure-volume relationship (LV-ESPVR) was assessed for 2 hours of
oxygenated blood reperfusion.
Results: All BD (n ¼ 5) and 4 DCD hearts were successfully resuscitated. One DCD heart was unable to be
resuscitated due to prolonged warm ischemic time (WIT; 174 minutes). Mean WIT for resuscitated DCD hearts
(from extubation to flushing with cold UW solution) was 34  3 minutes (range, 26 to 40 minutes); mean cold
ischemic time for BD donors was 211  31 minutes compared with 177  64 minutes for DCD donors. The
calculated LV-ESPVRs for BD hearts after 1 and 2 hours of reperfusion were 6.9  0.7 and 5.7  1.0 mm
Hg/mL, respectively; LV-ESPVRs for DCD hearts after 1 and 2 hours of reperfusion were 5.6  1.5
(P ¼ .45) and 3.0  0.7 mm Hg/mL (P ¼ .07), respectively.
Conclusions:We successfully resuscitated and measured ex vivo cardiac function in human DCD and BD donor
hearts. Resuscitation potential in DCD hearts was achieved when the WITwas less than 40 minutes. Contractile
performance in DCD hearts tended to be lower compared with BD hearts. Further investigation with longer
reperfusion periods seems warranted. (J Thorac Cardiovasc Surg 2014;148:1123-30)Heart transplantation is an established and effective treat-
ment for patients with end-stage heart failure; however,
the shortage of donor organs is the most critical problem.
The Organ Procurement and Transplantation Network
(OPTN) reports indicate that the number of registrations
on the heart waiting list is approximately 3000 in a recent
3-year period and 15% of patients die within 1 year while
awaiting a donor heart (http://optn.transplant.hrsa.gov/).
To maintain or increase the present transplantation rate,
donation after cardiac death (DCD) donors have been
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Xtransplantation using DCD donors existed in the 1960s
before brain death became legally accepted and the first suc-
cessful clinical human heart transplantation in an adult was
performed using aDCDheart allograft in 1967 byChristiaan
Barnard.1 In the current era, Boucek and collegues2 reported
the short-term results of 3 infants undergoing successful
orthotopic heart transplantation from DCD donors. For
noncardiac organ transplantation, clinical studies from
several institutions show that DCD donors are reliable donor
sources for organs such as kidney3 and liver.4 The OPTN
data show a progressive increase in the rate of organ recov-
ery from DCD donors (1089 DCDs in 2012, compared with
189 in 2002) and that these donors accounted for 12% of all
deceased donors in 2012 (http://optn.transplant.hrsa.gov/).
In particular, at several Organ Procurement Organization
programs, DCD donors accounted for more than 20% of
all deceased donors. Although the use of DCD donors for
noncardiac organ transplant has been increasing, the poten-
tial for heart transplantation from DCD donors remains un-
realized, because of potentially severe myocardial damage
due to unavoidable warm ischemia (from the withdrawal
of life support to flushing with cold preservative solution).
According to the 1995 Maastricht categories,5 DCD
donors are classified as uncontrolled or controlled donors.diovascular Surgery c Volume 148, Number 3 1123
Abbreviations and Acronyms
BD ¼ brain dead
CIT ¼ cold ischemic time
DCD ¼ donation after cardiac death
LV-EDP ¼ left ventricular end diastolic
pressure
LV-ESP ¼ left ventricular end systolic
pressure
LV-EDPVR ¼ left ventricular end diastolic
pressure-volume relationship
LV-ESPVR ¼ left ventricular end systolic
pressure-volume relationship
LV dP/dt max ¼ left ventricular maximum of first
derivative of pressure
LV dP/dt min ¼ left ventricular minimum of first
derivative of pressure
LVP ¼ left ventricular pressure
OPTN ¼ Organ Procurement and
Transplantation Network
UW ¼ University of Wisconsin
UWHC-OPO ¼ University of Wisconsin Hospital
and Clinics-Organ Procurement
Organization
WIT ¼ warm ischemic time
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XUncontrolled donors are dead on arrival (category I) or had
an unsuccessful resuscitation (category II). Controlled do-
nors have an awaited cardiac arrest (category III) or develop
cardiac arrest while brain dead (category IV). The so-called
Maastricht category III, withdrawal of donor treatment
(usually in the intensive care unit or operating room), is a
controlled DCD technique and the only one presently in
use in the United States, including our institution. This cate-
gory III DCD donor could potentially be used for clinical
heart transplantation.
Over the past decades, many animal experiments have
been undertaken to evaluate the feasibility of heart trans-
plantation from DCD donors, using various reperfusion
strategies and animal DCD models. Some researchers
indicated excellent results in animal DCD heart
transplant experiments. Shirakura and colleagues6 reported
satisfactory functional recovery of canine hearts after a
24-hour period of preservation in a 30-minute warm
ischemic DCD transplant model, and Gundry and col-
leagues7 achieved long-term survival of baboons receiving
transplantation of hearts harvested from 30-minute warm
ischemic DCD donors. However, these successful experi-
mental outcomes are largely attributable to the application
of multiple pretreatments, which, in humans, would be
ethically unacceptable. In our previous animal studies,8,9
we evaluated acute posttransplant graft function using a
30-minute warm ischemic pig DCD model without any1124 The Journal of Thoracic and Cardiovascular Surcardioprotective pretreatments except for heparin, and this
graft functional recovery rate was approximately 80% of
the pretransplant (normal) value. These animal studies
support the potential acceptability of 30-minute warm
ischemic DCD cardiac grafts. However, the acceptability
of warm ischemic time (WIT) for human adult DCD
hearts is still unknown because resuscitation potential and
functional recovery after warm ischemia have not yet
been elucidated.
The purpose of this study was to evaluate the resuscita-
tion potential and contractile function in adult human
DCD hearts using an ex vivo perfusion system and
investigate functional recovery for human DCD hearts
compared with human brain dead (BD) hearts.
MATERIALS AND METHODS
DCD and BD Donors
Five BD and 5 DCD donor hearts were evaluated in this study, with
institutional review board approval and using the deceased donor
(BD and DCD) protocol in the University of Wisconsin Hospital and
Clinics-Organ Procurement Organization (UWHC-OPO).10
All DCD donor hearts were obtained from donors eligible for other
organ transplant protocols in the UWHC-OPO, who agreed to donate the
heart for research purposes. Each organ was checked separately on the
consent form. All DCD donors in this study were brought to the operating
room before the withdrawal of life support. While the patient was fully
supported, 30,000 units of heparin were given intravenously to facilitate
subsequent organ flushing. The patient’s physician of record withdrew
life support by stopping intravenousmedications and extubation. The organ
recovery procedure commenced only after an additional 5 minutes elapsed
after the declaration of death, as described in the 1997 Institute of Medicine
Guidelines.11 Five minutes after the declaration of death, median
sternotomy and a midline abdominal incision were made and the inferior
vena cava was dissected immediately to decompress the heart. All DCD
hearts were asystolic when they were explanted. After organ recovery for
clinical transplantation, the ascending aorta was cannulated and
approximately 2 L of UW solution was infused in situ. Then the heart
was removed en bloc, stored in UW solution at 4C, and transported to
our research laboratory.
All BD hearts were obtained from donors who were ineligible for our
BD heart transplant protocol, and who agreed to donate the heart for
research purposes. Each organ was checked separately on the consent
form. All BD hearts were preserved using our institutional method of
BD heart recovery. After administration of 30,000 units of heparin, the
ascending aorta was clamped and approximately 2 L of UW solution was
infused through the aortic cannula. The inferior vena cava was divided
immediately to decompress the heart. The heart was removed en bloc
and stored in UW solution at 4C.
WITwas defined as the interval between withdrawal of life support and
cold flush of UW solution; cold ischemic time (CIT) was defined as the
interval between cold flush and oxygenated blood reperfusion of the graft.
Ex Vivo Myocardial Perfusion System
The perfusion circuit was an open system and the reperfusion protocol
was similar to that previously described (Figure 1).9 The system consisted
of a Terumo pediatric membrane oxygenator with the reservoir containing
a filter (Terumo Cardiovascular Systems, Ann Arbor, Mich), a circulating
water bath, a hemofilter, a roller head pump, a temperature meter, a
leukocyte-depletion filter (Pall, Glen Cove, NY), and 6.4-mm (0.25-inch)
connective tubing. A new circuit was used for each procedure in a
semisterile manner. The total circuit volumewas 600mL. Coronary venousgery c September 2014
FIGURE 1. Ex vivo perfusion system.9
TABLE 1. Donor characteristics
Type of
donor
Age
(y) Gender
Cause of
brain death
or major
brain injury
WIT
(min)
CIT
(min) Resuscitation
BD 1 54 Female Anoxia 0 115 Yes
BD 2 50 Female Anoxia 0 293 Yes
BD 3 21 Female Anoxia 0 251 Yes
BD 4 59 Male ICH 0 178 Yes
BD 5 66 Male Stroke 0 220 Yes
DCD 1 31 Female Head trauma 174 53 No
DCD 2 36 Female Stroke 40 77 Yes
DCD 3 58 Female ICH 32 349 Yes
DCD 4 56 Male Head trauma 26 83 Yes
DCD 5 55 Female ICH 36 198 Yes
WIT, Warm ischemic time (from withdrawal of life support to cold flush of University
of Wisconsin solution); CIT, cold ischemic time (from cold flush to oxygenated blood
reperfusion); BD, brain dead; DCD, donation after cardiac death; ICH, intracranial
hemorrhage.
Osaki et al Cardiothoracic Transplantation and Mechanical Circulatory Support
T
Xblood drained spontaneously and thebesian flow drained through stab
wounds in the right and left ventricles, all of which was collected in a large
funnel and directed to the reservoirwhere it waswarmed by an internal heat-
ing element via thewater bath. The bloodwas then drawn from the reservoir
by the roller head pumpand passed through the hemofilter on its return to the
membrane oxygenator. This oxygenated blood was passed through the
leukocyte-depletion filter and pumped to the upper small blood reservoir.
Then leukocyte-depleted oxygenated blood was perfused through the
coronary arteries by gravity. This circuit was primedwith 4 units of recently
outdated, type-specific, and noncrossmatched packed human red blood cells
and crystalloid, such as lactated Ringer and 5% dextrose solutions. The
human red blood cells were washed to remove excess potassium and citrate
by mixing with 1000 mL of normal saline solution. Two hundred units of
heparin and 300mg of calcium gluconatewere added to each unit of packed
cells. An additional 1000 units of heparin were added to the circuit. The
prime was recirculated through the system via a heated water bath and the
perfusate reached 20C. Before the heart was reperfused, corrective
measures were required to adjust the sodium concentration, chloride
concentration, potassium concentration, pH, and calcium concentration of
the perfusate to make the solution physiologic, and these values were
equivalent between the groups. The perfusate was oxygenated through the
membrane oxygenator with an admixture of compressed air and carbogen
(5% CO2, 21% O2, and balance N2). The percentage of carbogen was
adjusted to maintain a carbon dioxide tension of 30 to 34 mm Hg. The
hemoglobin oxygen saturation was 100% throughout the experiment as
determined by periodic blood gas determinations.
For reperfusion, after the hearts were transported to our laboratory, a
custom aortic cannula was connected to the aortic root. For the controlled
initial perfusion, 4:1 leukocyte-depleted blood cardioplegia was infused
for 20 minutes at 20C with a perfusion pressure of 40 mm Hg. The first
solution that passed through the heart was discarded into a vacuum bucket.
After the initial reperfusion, myocardial perfusion was then resumed with
leukocyte-depleted oxygenated blood at 20C with a perfusion pressure ofThe Journal of Thoracic and Car40 mm Hg. The perfusion pressure was increased to 80 mm Hg and the
temperature was increased stepwise to 37C over the next 30 minutes.
All blood parameters were monitored throughout the experiment by blood
gas examination, and were corrected to be within physiologic range. If the
hearts were fibrillating while rewarming, electric cardioversion with
ventricular pacing was used as needed.
Measurement of Contractile Function
Isovolumetric left ventricular pressure (LVP) was measured for 2 hours
with a transducer connected to a thin, saline-filled latex balloon inserted
into the left ventricle through the mitral valve from an incision in the left
atrium. Balloon volume was adjusted initially to a diastolic LVP of
0 mm Hg so that any subsequent increase in diastolic LVP reflected an
increase in left ventricle wall stiffness (ie, diastolic contracture). Left
ventricular end systolic pressure-volume relationship (LV-ESPVR) and
left ventricular end diastolic pressure-volume relationship (LV-EDPVR)
were calculated from pressure-volume relation curves obtained by
changing the balloon volume. Left ventricle maximum and minimum of
the first derivative of pressure (dP/dt max and dP/dt min, respectively)
were obtained from a pressure curve acquired from a high-fidelity
micromanometer catheter (Miller Instruments, Houston, Tex). Left
ventricular systolic (LV-ESPVR and dP/dt max) and left ventricular
diastolic (LV-EDPVR and dP/dt min) functions were analyzed.
Statistical Analysis
Statistical significance of any difference between the BD and DCD
hearts was determined with an independent sample t test. The results are
given as the mean  standard error. All analyses were performed using
the SPSS for Windows version 22.0 (SPSS Inc, Chicago, Ill).RESULTS
Donor Characteristics
The donor characteristics are shown in Table 1. The mean
age of all donors was 49  14 years old. The mean age was
not different between the groups (BD vs DCD; 50 8 vs 47
 6 years; P¼ .78). Seven donors were female (3 BD and 4
DCD donors). Causes of brain death or major brain injury
were anoxia for 3 DCDs, intracranial hemorrhage for 1
BD and 2 DCDs, stroke for 1 BD and 1 DCD, and headdiovascular Surgery c Volume 148, Number 3 1125
TABLE 2. Contractile function for BD and DCD hearts
60 min after reperfusion 90 min after reperfusion 120 min after reperfusion
dP/dt max for BDs (mm Hg/s) 983  102 969  77.6 801  112
dP/dt max for DCDs (mm Hg/s) 781  270 734  180 481  161
P value .56 .30 .16
LV-ESPVR for BDs (mm Hg/mL) 6.9  0.7 6.4  0.9 5.7  1.0
LV-ESVPR for DCDs (mm Hg/mL) 5.6  1.5 5.0  1.1 3.0  0.7
P value .45 .36 .07
dP/dt min for BDs (mm Hg/s) 576  48.1 544  63.3 511  71.8
dP/dt min for DCDs (mm Hg/s) 507  130 496  70.3 332  93.1
P value .67 .62 .18
LV-EDPVR for BDs (mm Hg/mL) 0.69  0.43 0.69  0.34 0.82  0.62
LV-EDPVR for DCDs (mm Hg/mL) 0.70  0.49 0.71  0.34 0.11  0.50
P value .98 .96 .41
BD, Brain dead donor; DCD, donation after cardiac death donor; dP/dt max, left ventricular maximum of first derivative of pressure; LV-ESPVR, left ventricular end systolic
pressure-volume relationship; dP/dt min, left ventricular minimum of first derivative of pressure; LV-EDPVR, left ventricular end diastolic pressure-volume relationship.
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Xtrauma for 2 DCDs. Heparin was administered to all DCD
donors before withdrawal of support. The mean WIT for
the 4 DCD hearts that were resuscitated by ex vivo
perfusion was 34  3 minutes (range, 26-40 minutes).
The mean CIT for BD donors was 211  31 minutes.
The mean CIT for the 4 resuscitated DCD hearts was
177  64 minutes, which was similar to that of BD hearts
(P ¼ .65). Reasons for declining clinical heart transplanta-
tion for BD donors were significant coronary artery disease
diagnosed by coronary angiogram for 3 donors, advanced
age for 1 donor, and complicated social history for 1 donor.
Resuscitation Potential and Contractile Function
Five BD (100%) and 4 DCD (80%) hearts were
successfully resuscitated and evaluated for contractile func-
tion. However, 1 DCD heart with 174 minutes of WIT did
not start to beat after oxygenated blood reperfusion.
Contractile function is shown in Table 2 and Figures 2
through 4. Left ventricular systolic functions (dP/dt max
and LV-ESPVR) for DCD hearts were comparable with
those of BD hearts at 60 and 90 minutes after reperfusion
(dP/dt max, P ¼ .56 at 60 minutes and P ¼ .30 at 90 mi-
nutes; LV-ESPVR, P ¼ .45 at 60 minutes and P ¼ .36 at
90 minutes), however, the values for DCD hearts at 120
minutes after reperfusion tended to be lower compared
with BD donors (dP/dt max, P ¼ .16; LV-ESPVR,
P ¼ .07). Left ventricular diastolic functions (dP/dt min
and LV-EDPVR) for DCD hearts were comparable with
those of BD hearts at 60 and 90 minutes after reperfusion
(dP/dt min, P ¼ .67 at 60 minutes and P ¼ .62 at 90
minutes; LV-EDPVR, P ¼ .98 at 60 minutes and P ¼ .96
at 90 minutes), however, the values for DCD hearts at 120
minutes after reperfusion tended to be lower compared
with BD donors, especially for dP/dt min (P ¼ .18).
DISCUSSION
This study is the first report to evaluate resuscitation
potential and ex vivo nonworking contractile myocardial1126 The Journal of Thoracic and Cardiovascular Surfunction in acute phase for human DCD hearts compared
with human discarded BD hearts. Ten deceased donor
hearts were evaluated in this study and 9 hearts including
5 BD and 4 DCDs within 40 minutes of WIT (90%) were
successfully resuscitated using our custom ex vivo isolated
myocardial perfusion system. Our study has shown that
ex vivo contractile function for 90 minutes of reperfusion
in the resuscitated human DCD hearts was comparable
with that of human BD hearts. However, after 2 hours of
reperfusion, the graft function for DCD donors tended to
deteriorate compared with BD hearts.
The major cause of DCD graft deterioration is warm
ischemic injury. Warm ischemia, commonly defined as
the interval of time between extubation (as the definitive
withdrawal of treatment) and the initiation of cold perfusion
for organ preservation, is unavoidable during the process of
donation after cardiac death or circulatory arrest.12,13 This
is the most critical concern for DCD allografts, because it
is not observed in the hearts of BD donors and causes
more severe graft injury than cold ischemia. The exposure
to warm ischemia leads to a significant deletion of
myocardial energy stores, anaerobic metabolism, and
development of intracellular acidosis,14 which eventually
causes myocyte death after reperfusion.15 Moreover, DCD
hearts would be forced to attempt to support an entire
circulatory load while functioning in an increasingly
hypoxic environment during the period from extubation to
cardiac arrest,16 whereas BD cardiac allografts do not suffer
such load impairments induced by hypoxia because cardiac
arrest is initiated by using cardioplegic solution and
venous drainage. In our previous animal study, we clearly
documented the changes in pressure and volume loads
during the increasing hypoxia in the DCD animal model;
the peak distending pressure was about 150% of baseline
and the peak ventricular distended volume was 132% of
baseline.17 These unfavorable and unavoidable injuries in
the DCD context can greatly affect the DCD cardiac graft
function.gery c September 2014
FIGURE 2. Contractile function for BD and DCD donors. BD, Brain dead; DCD, donation after cardiac death; LV-ESPVR, left ventricular end systolic
pressure-volume relationship.
Osaki et al Cardiothoracic Transplantation and Mechanical Circulatory SupportSeveral animal DCD heart transplant studies have been
conducted to elucidate the feasibility of DCD cardiac
allografts under these unfavorable conditions, and to
evaluate their functional recovery after transplant and the
acceptable limits of WIT.6-9 Although several species
such as pig,8,9 dog,6 and baboon7 were used and variousFIGURE 3. Individual comparison and trend line of LV-ESPVR in BD an
B, Individual comparison of LV-ESPVR for DCD hearts. C, Trend line of LV-ES
dead; DCD, donation after cardiac death; LV-ESPVR, left ventricular end systo
The Journal of Thoracic and Carstrategies of reperfusion and organ preservation were
applied to these studies, the results support the potential
acceptability of up to 30 minutes of WIT. Gundry and
colleagues7 achieved long-term survival of baboons
receiving transplantation of hearts harvested from DCD
donors within 30 minutes ofWIT. However, at the structurald DCD hearts. A, Individual comparison of LV-ESPVR for BD hearts.
PVR for BD hearts. D, Trend line of LV-ESPVR for DCD hearts. BD, Brain
lic pressure-volume relationship; WIT, warm ischemic time.
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FIGURE 4. Individual left ventricular end systolic pressure-volume relationship (LV-ESPVR) and left ventricular end diastolic pressure-volume
relationship (LV-EDPVR) plots in BD and DCD hearts at 90 minutes of reperfusion. A, Individual LV-ESPVR plots for BD hearts. B, Individual
LV-ESPVR plots for DCD hearts. C, Individual LV-EDPVR plots for BD hearts. D, Individual LV-EDPVR plots for DCD hearts. LV-ESP, Left ventricular
end systolic pressure; BD, brain dead; DCD, donation after cardiac death; LV-EDP, left ventricular end diastolic pressure.
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Xlevel, global warm ischemia of 20 minutes can result in
irreversible ischemic injury (ie, isolated cell death or tiny
islands of cell death).18
To date, the clinical experience of human DCD heart
transplantation has been limited and only a few case reports
have been published. The first 2 adult human heart
transplantations performed by Christiaan Barnard in
19671 and 196819 were from DCD donors because there
was no formal definition of brain death at that time. Both
recipients showed remarkable recovery and reversibility
of heart failure symptoms after transplant, however, the first
patient died as a result of pneumonia on postoperative day
18 and the second patient survived for 18 months before
dying from chronic rejection. There was no detailed
information on the interval from withdrawal of care to
cardiac arrest for these 2 DCD donors, except the time
from certification of death to initiation of median sternot-
omy was 5 minutes. The first pediatric human DCD heart
transplantation was reported by Boucek and colleagues2
in 2008. According to this report, the mean WIT was 18.3
minutes (11.5, 16.0, and 27.5 minutes, respectively) and
the 6-month survival was 100% for the 3 DCD heart
transplant recipients, compared with 84% survival for 17
control infants who received transplants procured through1128 The Journal of Thoracic and Cardiovascular Surstandard organ donation. These DCD heart transplant
recipients have had functional and immunologic outcomes
similar to those of controls. A possible greater tolerance
for global warm ischemia of the immature myocardium
needs to be considered compared with the adult heart
because of physiologic features in immature hearts.20
Recently, 2 case reports regarding postresuscitated
functional evaluation for human DCD hearts have been
published.21,22 Ali and colleagues21 reported biventricular
cardiac functional recovery in a human DCD donor
resuscitated by using an extracorporeal perfusion after
cardiac death. The donor was a 57-year-old woman
with irreversible neurologic damage from intracranial
hemorrhage. The WIT from extubation to initiation of
extracorporeal perfusion was 24 minutes and there was no
cold ischemia. The heart was able to support the circulation
for 37 minutes with good cardiac function, except for an
abnormality in the right ventricular pressure-volume loop
morphology. Rosenfeldt and collegues22 evaluated the heart
donated after cardiac death from a 42 year-old man who
developed irreversible neurologic damage from anoxia by
using their custom ex vivo perfusion system. The WIT for
this heart was 32 minutes. The heart maintained adequate
left ventricular pressure over 12 hours with epinephrinegery c September 2014
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Xsupport. In our study, 4 human DCD hearts were
resuscitated by our ex vivo perfusion method, except for 1
DCD heart with prolonged WIT of 174 minutes. The WIT
of 4 resuscitated DCD hearts was within 40 minutes and
the mean CIT was 152  55 minutes. Our study shows
that the contractile function of human DCD hearts for the
first 90 minutes of reperfusion was comparable with that
of BD hearts, however, DCD heart function tended to
deteriorate after 2 hours of reperfusion. Although previous
experiments and our results suggest that WIT in the range of
30 to 40 minutes may be acceptable, because of the
potential for severe myocardial damage, it is likely that
the ideal WIT for clinical adult human DCD heart
transplantation would bewithin 20minutes although further
studies are warranted to establish the relationship between
WIT and myocardial viability.
It is reasonable to expect that diastolic function in DCD
donor hearts would be impaired due to several factors
present in ischemic myocardium, including derangements
in calcium homeostasis as a result of reduced uptake of
Ca2þ into the sarcoplasmic reticulum by the sarco-/
endoplasmic reticulum Ca2þ-ATPase and alterations in
the function of the membrane bound sodium-calcium
exchanger.23 In addition, prolonged duration of ischemia
would reduce cardiac contractile function as a result of
the deleterious effects of ischemia-reperfusion injury,
ultimately reducing the amount of viable myocardium and
leading to impaired cardiac relaxation and diastolic
dysfunction. In light of these considerations, a limitation
of our model arises from the inability to adequately describe
diastolic dysfunction as it would pertain to DCD hearts. Our
data did not show a statistical difference in diastolic func-
tion between BD and DCD hearts (dP/dt min of DCD hearts
deteriorated more after 120 minutes of reperfusion than that
of BD hearts). However, as shown in Figure 4, end diastolic
pressure decreases with wider deviation in some BD and
DCD hearts with increased balloon volume, a result
that was unexpected. It is likely due to experimental
considerations such as instability of the intraventricular
balloon position with increasing balloon volume, especially
in the diastolic phase. This suggests that the diastolic
pressure measurements in this study may not reflect the
exact diastolic pressures and future studies of diastolic
dysfunction in DCD hearts are warranted.
Study Limitations
This study has some limitations. First, the sample size is
small, which could affect the results of the statistical
analysis. Second, although cardiac function of the BD
donor hearts that were evaluated in this study was nearly
normal before donation, most of the BD donors were
declined for clinical heart transplantation because of
atherosclerotic disease in the coronary artery. This
indicates that these BD hearts may not be appropriate toThe Journal of Thoracic and Carbe considered as a control group. For the DCD donors,
pretransplant cardiac evaluation such as transthoracic
echocardiography or coronary angiogram was not
completed because these DCD donors were not considered
as clinical cardiac donors. Third, our functional evaluation
was an ex vivo nonworking beating heart model and this
concept is originally from the Langendorff preparation,
which was not able to evaluate in vivoworking biventricular
cardiac function. Fourth, the donor hearts were functionally
evaluated only for the acute phase (the 90-minute time
window) in this study. This is a major weakness of this
study. Possible reasons for early functional deterioration
in this study could be impairment of coronary perfusion
by the intraventricular balloon, the semisterile perfusion
technique without using antibiotics, and inappropriate
perfusion solution without adding a high-osmotic solution
such as albumin solution. Therefore, further evaluation for
longer perfusion periods is required to confirm our findings.
Currently, a portable ex vivo heart perfusion system is being
clinically investigated as a means to optimize the use of
BD hearts.24 This system can facilitate the delivery of
pharmaceutical agents that support reparative processes in
ischemic myocardium and the assessment of graft function
before transplantation.25-28 This may be also useful for graft
evaluation for longer perfusion periods.22CONCLUSIONS
We successfully resuscitated and measured ex vivo
cardiac function in human DCD and BD donor hearts.
Our study has shown that the resuscitation potential in
DCD hearts was achieved when the WIT was less than 40
minutes and ex vivo contractile function for 90 minutes of
reperfusion in the resuscitated human DCD hearts was
comparable with that of human BD hearts. However, after
2 hours of reperfusion, the graft function for DCD donors
tended to deteriorate compared with the BD hearts.
Although our functional observation was only for the acute
phase and further evaluation is necessary to confirm our
findings, our results indicate that human DCD hearts within
optimal warm ischemia might be another donor source for
adult cardiac transplantation.
The authors thank James E. Anderson, transplant coordinator at
UWHC-OPO for assistance with DCD donor data collection.References
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Dr Richard-Tien V. Ha (Stanford, Calif). Dr Osaki, thank you
for providing me the manuscript ahead of time and also
congratulations on the research that you have done. I think this
is something that we will be talking about more in the future.
As you know, your laboratory, as well as other laboratories,
have looked at animal hearts in the DCD condition. And although
those results have been promising, there are a lot of hurdles to
overcome. I listened with interest to your presentation and read
your manuscript. And I think what stands out is that you used hu-
man hearts really for the first time in a DCD condition and used an
ex vivo apparatus to try to recondition or look at their function.
The other thing that was very interesting about your paper was
the fact that you chose to use a functional, or at least start to use a
functional assessment rather than just biochemical assessments for
the hearts, which is something novel as well.
To that end I have 2 questions for you.
The first question relates to the functional assessment. And you
mentioned that it was a nonworking heart model, but in the future
do you plan to assess a working heart model where you vary the
preload and the afterload and challenge the heart in that condition?
The second question is: the studies that have been done by Ali
and other laboratories in animals have looked at and discussed
that the RV is actually a key component in the failure of
these DCD hearts. Did you observe the RV at all during this
time—understandably it’s in a Langendorff model—or are you
planning to do that in the future?
Dr Osaki. Thank you very much, Dr Ha. It’s a very good
comment.
For the first question, actually we didn’t change the afterload
but we changed the preload by the balloon volume. Yes, absolutely,
in the future, we need to do an in vivo setting as a nice functional
variation.
And also the second question, in this study we didn’t look at the
right heart function; as we know, there is 1 case report for
biventricular functional evaluation for the human DCD heart,
and that’s a great study. Yes, absolutely, we are planning to do
biventricular function analysis.gery c September 2014
